# Software Requirements Specification

for

# PCOCare using Machine Learning

Version 1.0 approved

Prepared by Aditi Singh, Pooja Kumari, Kirti Jayant

**KIET Group of Institutions** 

19th April,2023

# **Table of Contents**

Ta	able	of Contents	ii
1.	Int	troductiontroduction	1
	1.1	Purpose	
	1.2	Document Conventions	
	1.3	Intended Audience and Reading Suggestions	1
	1.4	Project Scope	
	1.5	References	
2.	Ov	verall Description	2
	2.1	-	
	2.2	Product Features	2
	2.3	User Classes and Characteristics	2
	2.4	Operating Environment	3
	2.5	Design and Implementation Constraints	3
	2.6	User Documentation	3
	2.7	Assumptions and Dependencies	3
3.	Sys	stem Features	4
	3.1	System Feature 1	4
	3.2	System Feature 2 (and so on)	5
4.	Ex	sternal Interface Requirements	Error! Bookmark not defined.
	4.1	_	
	4.2	Hardware Interfaces	Error! Bookmark not defined.
	4.3	Software Interfaces.	Error! Bookmark not defined.
	4.4	Communications Interfaces	Error! Bookmark not defined.
5.	Ot	ther Nonfunctional Requirements	Error! Bookmark not defined.
	5.1		
	5.2		
	5.3	Security Requirements	
	5.4	• 1	

#### 1. Introduction

#### 1.1 Purpose

The purpose of this document is to build a website for PCOS Detection and Prediction System which would help the women of reproductive age and teenage girls to get information regarding their increased health risks and Symptoms and conditions of PCOS hence making it easier for women to get the knowledge about their health.

#### 1.2 Document Conventions

DB	Database
DS	Data Set
ER	Entity Relationship

### 1.3 Intended Audience and Reading Suggestions

This project is a prototype for PCOS Detection and Prediction and it is restricted within the college premises. This has been implemented under the guidance of college professors. This project is useful for the patients of PCOS, young girl child in teenage, women of reproductive age, doctors.

### 1.4 Project Scope

Polycystic ovary syndrome (PCOS) is a heterogeneous disorder characterized by hyperandrogenism and chronic anovulation. Depending on diagnostic criteria, **6% to 20% of reproductive aged women are affected**. Symptoms of PCOS arise during the early pubertal years. Our goal is gto reach the selected audience who are at hogher risk of having PCOS.

# 1.5 References

https://www.researchgate.net/publication/348627784\_PCOcare\_PCOS\_Detection\_and\_Prediction\_using\_M\_achine\_Learning\_Algorithms


https://www.frontiersin.org/articles/10.3389/fendo.2021.789878/full

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9556522/

# 2. Overall Description

#### 2.1 Product Perspective

Polycystic Ovary Syndrome (PCOS) is a medical condition which causes hormonal disorder in women in their childbearing years. The hormonal imbalance leads to a delayed or even absent menstrual cycle. Women with PCOS majorly suffer from excessive weight gain, facial hair growth, acne, hair loss, skin darkening and irregular periods leading to infertility in rare cases. The existing methodologies and treatments are insufficient for early-stage detection and prediction. To deal with this problem, we propose a system which can help in early detection and prediction of PCOS treatment from an optimal and minimal set of parameters. To detect whether a woman is suffering from PCOS, 5 different machine learning classifiers like Random Forest, SVM, Logistic Regression, Gaussian Naïve Bayes, K Neighbours have been used. Out of the 41 features from the dataset, top 30 features were identified using CHI SQUARE method and used in the feature vector. We also compared the results of each classifier and it has been observed that the accuracy of the Random Forest Classifier is the highest and the most reliable.



# 2.2 Product Features

Emerging technologies are reshaping mankind in a lot of ways. These days, machine learning, a field of study that gives computers to learn without being explicitly programmed, is playing a key role in the healthcare sector. Machine learning can deal with obscenely huge datasets, convert analysed data into clinical insights and help in the diagnosis of various ailments. Polycystic Ovary Syndrome (PCOS) is a medical

condition which causes hormonal disorder in women in their childbearing years. PCOS occurs as a result of hormonal imbalances. In this disorder, the ovaries develop small collections of fluids called follicles (cysts) and fail to release eggs, which is why women suffering from PCOS tend to have complications in conceiving [Zhang, 2018]. A lot of women have PCOS, but do not get diagnosed with it at an earlier stage.

The formulation of a good machine learning model is an important aspect of project design. Having the correct patient data is very important because one cannot afford mistakes while devising healthcare services. We have used multiple machine learning models to check which model gives us the most accurate results. To support our claims and results obtained, use of plots and evaluation metrics has been made. A basic workflow diagram to explain the proposed system is given in Figure 1. The following sections will give a detailed insight into the system.

# 2.3 Operating Environment

These days, machine learning, a field of study that gives computers to learn without being explicitly programmed, is playing a key role in the healthcare sector. Machine learning can deal with obscenely huge datasets, convert analysed data into clinical insights and help in the diagnosis of various ailments. Polycystic Ovary Syndrome (PCOS) is a medical condition which causes hormonal disorder in women in their childbearing years. PCOS occurs as a result of hormonal imbalances. In this disorder, the ovaries develop small collections of fluids called follicles (cysts) and fail to release eggs, which is why women suffering from PCOS tend to have complications in conceiving [Zhang, 2018]. A lot of women have PCOS, but do not get diagnosed with it at an earlier stage.

#### 2.4 User Documentation

Components that will be delivered along with the software:

- 1. Software Requirement Specification
- 2. Specification Manual
- 3. Working Manuals
- 4. Tutorial Manuals

# 2.5 Assumptions and Dependencies

The overall aims of treatment are to induce ovulation for women desiring conception, to reduce androgen levels, to reduce body weight and to reduce long-term health risks of diabetes mellitus and cardiovascular disease. Polycystic ovary syndrome (PCOS) is one of the most common reproductive, endocrine, and metabolic disorders in premenopausal women. Clinically,

PCOS is mainly caused by androgen excess and ovarian dysfunction, manifested by anovulatory menstrual cycles, infertility, and hirsutism.

## 3. System Features

The formulation of a good machine learning model is an important aspect of project design. Having the correct patient data is very important because one cannot afford mistakes while devising healthcare services. We have used multiple machine learning models to check which model gives us the most accurate results. To support our claims and results obtained, use of plots and evaluation metrics has been made .

#### 3.1.1 Description and Priority

The most common symptoms of this disorder may include missed periods, irregular periods, or very light periods, it affects in a way that ovaries become large or may contain many cysts, it can also cause excess body hair, including the chest, stomach, and hirsutism, can cause weight gain, especially around the abdomen, Acne or oily skin. The exact pathophysiology of PCOS is not yet known. This heterogenous disorder is characterized by the ovaries mainly. PCOS is a multifactorial and polygenic condition.

#### 3.1.2 Functional Requirements

- Data Set of the PCOS patients
- Data Set of p atients with higher risk of PCOS
- Data Set of women of reproductive Age
- Data Set of infertility rate in women of reproductive age

0	28	44.6	152	19.3	15	78	22	10.48	2		7	0	0	7.95	3.68	36	30	0.68	2.07	45.16	17.1	0.57		
0	36	65	161.5 2		15	74	20	11.7	2			1	0	6.73	1.09	38	32	3.16	1.53	20.09	61.3	0.97		
1	33	68.8		5.27089	11	72	18	11.8	2			1	0	5.54	0.88	40	36	2.54	6.63	10.52	49.7	0.36		
0	37	65		9.67495	13	72	20	12	2			0	0	8.06	2.36	42	36	16.41	1.22	36.9	33.4	0.36		
0	25	52		0.06095	11	72	18	10	2			1	0	3.98	0.9	37	30	3.57	2.26	30.09	43.8	0.38		
0	36	74.1		7.21763	15	78	28	11.2	2		-	1	0	3.24	1.07	44	38	1.6	6.74	16.18	52.4	0.3		
0	34	64		6.29849	11	72	18	10.9	2			0	0	2.85	0.31	39	33	1.51	3.05	26.41	42.7	0.46		
0	33	58.5		3.13991	13	72	20	11	2			1	2	4.86	3.07	44	38	12.18	1.54	3.97	38	0.26		
0	32	40		6.02307	11	72	18	11.8	2			0	1	3.76	3.02	39	35	1.51	1	19	21.8	0.3		
0	36	52		3.11111	15	80	20	10	4			0	0	2.8	1.51	40	38	6.65	1.61	11.74	27.7	0.25		
0	20	71		6.72287	15	80	20	10	2			1	2	4.89	2.02	39	35	1.56	4.47	13.47	18.1	0.36		
0	26	49	160 1	9.14063	13	72	20	9.5	2		-	0	1	4.09	1.47	39	33	3.98	1.67	21.1	29.18	0.25		
1	25	74	152 3	2.02909	17	72	18	11.7	4		2 7	1	0	2	1.51	45	40	6.51	7.94	22.43	31.4	0.3		
0	38	50	152 2	1.64127	13	74	20	12.1	2		15	0	0	4.84	0.71	39	33	1.48	2.38	15.62	21.2	0.4		
0	34	57.3	162 2	1.83356	13	74	22	11.7	2		9	0	0	7.45	3.71	38	30	1.51	0.88	19.6	24.9	0.26		
0	38	80.5	154 3	3.94333	13	78	22	11.4	2		20	0	0	9.51	2.51	44	41	1.18	0.69	92.65	9.7	0.3		
0	29	43	148 1	9.63112	13	80	20	11.1	2		5 2	1	0	2.02	0.65	36	29	1.98	3.78	20.25	19.1	0.46		
0	36	69.2		7.03125	13	72	18	10.8	2		5 7	0	0	4.86	2.96	39	32	5	1.92	12.52	26	0.25		
0	31	52.4		0.72703	17	72	18	12.7	2			0	0	6.05	1.05	37	33	3.19	1	12.05	23.3	0.25		
1	30	85		31.2213	16	72	18	12.5	4			0	0	1.89	0.81	44	42	2.87	2.07	19.13	28	0.3		
0	25	64		6.29849	11	70	18	11.2	2			0	0	2.82	1.3	39	34	1.86	2.85	33.62	17.1	0.4		
0	38	50		0.54569	15	72	18	11	4			1	0	3.18	2.18	36	29	5.71	2.13	40.74	18.9	0.3		
0	34	64.2		6.72216	15	74	20	12.1	2			1	0	4.08	2.10	36	32	1.25	4.13	13.38	28.6	0.26		
0	28	65		8.13366	13	74	22	10.5	2			1	0	6.41	1.69	37	33	0.45	2.5	17.88	30.54	0.73		
1	34	63		5.23634	11	72	20	11.2	2			1	0	5.34	0.89	38	32	0.65	1.89	11.46	21.5	0.98		
0	41	42		8.17867	12	80	20	11.5	2			1	0	8.82	4.39	39	32	0.84	0.26	17.35	45.6	0.98		
1	30	76		29.6875	15	75	18	11.2	4	3		0	0	6.18	2.78	45	38	4.28	3.84	17.98	25.14	0.35		
0	20	68	152 2	9.43213	17	72	20	10	4	3	3 4	1	0	1.8	0.41	40	33	8.39	2.5	11.24	46.3	1.2		
0	25	62	158 2	4.83576	15	78	22	11.6	2		5 8	0	0	4.6	1.06	42	34	3.79	3.56	15.3	36.56	0.25		
1	28	56	152 2	4.23823	13	78	22	11	4	3	3 7	0	0	2.41	1.19	40	33	3.44	1.56	45.47	23.14	0.63		
	22	50	155 2	0.81165	17	78	22	10.8	2		3.5	1	0	6.34	4.07	34	28	1.4	1.69	54.09	56.2	0.31		
0	32								2	4	15	0	0	5.01	6.48	40	37	4 21 A	ctiy.85e	W12.710V	/S22.45	0.27		
0	34	57	150 2	5.33333	11	72	22	12	2															
1 0		57 58	155 2	4.14152	15	72	18	10.5	2		eight gai hair	0	0	2.8	0.42	39	32	1.88 Go	to <b>2</b> :34tin	gs <b>23.74</b> livi	ate <b>32 i 2</b> do	ows. <b>0.52</b>	size Avg	ą. F siz
1 0 IU/r LH(r	34 31 mIU/m H 3.68	57 58 lip(inch)	155 2 Waist(incl	4.14152 h TSH (mIU/ 0.68	15 AMH(ng/m 2.07	72 PRL(ng/mL 45.16	18 Vit D3 (ng 17.1	10.5 / PRG(r	2 ng/ml RBS 0.57	(mg/dl W 92	5 2 'eight gai hair 0	0 growt Skin	0 darkei Hai	2.8 ir loss(Y Pir	0.42 mples(Y/ Fas	39 It food (Re	32 g.Exerci E 0	1.88 Go BP _Systol I 110	BP_Diasto	gs23.74 iv	o Follicle N	No Avg. F	18	18
1 0 IU/r LH(r .95 i.73	34 31 mIU/m H 3.68 1.09	57 58 lip(inch) 36 38	155 2 Waist(incl 30 32	4.14152 h TSH (mIU/ 0.68 3.16	15 AMH(ng/m 2.07 1.53	72 PRL(ng/mL 45.16 20.09	18 Vit D3 (ng 17.1 61.3	10.5 / PRG(r	2 ng/ml RBS 0.57 0.97	(mg/dl W 92 92	eight gai hair 0 0	growt Skin	0 darke Hai 0 0	ir loss(Y Pir	0.42 mples(Y/ Fas 0 0	39 t food (Re 1 0	32 g.Exerci E 0 0	1.88 GO	BP_Diasto 80 70	gs23.74 ivo	ate 32.2 do	No Avg. F 3 5	18 15	1
1 0 IU/r LH(r .95 i.73 i.54	34 31 mIU/m H 3.68 1.09 0.88	57 58 Hip(inch) 1 36 38 40	155 2 Waist(incl 30 32 36	4.14152 h TSH (mIU/ 0.68 3.16 2.54	15 AMH(ng/m 2.07 1.53 6.63	72 PRL(ng/mL 45.16 20.09 10.52	18 Vit D3 (ng 17.1 61.3 49.7	10.5 / PRG(r	2 ng/ml RBS 0.57 0.97 0.36	i(mg/dl W 92 92 84	eight gai hair 0 0	0 growt Skin 0 0 0	darke Hai	2.8 ir loss(Y Pir 0 0 1	0.42 mples(Y/ Fas 0 0	39 at food (Re 1 0 1	g.Exerci E 0 0	1.88 Go	BP_Diasto 80 70	gs23.74 live Follicle No 3 3	o Follicle N	No Avg. F 3 5	18 15 18	1:
1 0 IU/r LH(r 1.95 1.73 1.54	34 31 mIU/m H 3.68 1.09 0.88 2.36	57 58 dip(inch) 1 36 38 40 42	155 2 Waist(incl 30 32 36 36	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41	AMH(ng/m 2.07 1.53 6.63 1.22	72 PRL(ng/mL 45.16 20.09 10.52 36.9	18 Vit D3 (ng 17.1 61.3 49.7 33.4	10.5 // PRG(n 1 3 7	2 ng/ml RBS 0.57 0.97 0.36 0.36	i(mg/dl W 92 92 92 84 76	eight gai hair 0 0 0	0 growt Skin 0 0 0 0 0	darke Hai	2.8 ir loss(Y Pir 0 0 1	0.42 mples(Y/ Fas 0 0 1 0	39 at food (Re 1 0 1	32 g.Exerci E 0 0 0	1.88 Go	BP_Diastr 80 70 80	gs23.74 ivo	o Follicle N	No Avg. F 3 5 5	18 15 18 15	1: 1: 2: 1:
1 0 U/r LH(r .95 i.73 i.54 i.06	34 31 mIU/m H 3.68 1.09 0.88 2.36 0.9	57 58 dip(inch) 3 36 38 40 42 37	155 2 Waist(incl 30 32 36 36	4.14152 h TSH (mIU/ 0.68 3.16 2.54 6 16.41 3.57	AMH(ng/m 2.07 1.53 6.63 1.22 2.26	72 PRL(ng/mL 45.16 20.09 10.52 36.9 30.09	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8	10.5 / PRG(r 1 3 7 4	2 0.57 0.97 0.36 0.36 0.38	92 92 84 76 84	eight gai hair 0 0	0 growt Skin 0 0 0 0 0 0	darke Hai	2.8 ir loss(Y Pir 0 0 1 0	0.42 mples(Y/ Fas 0 0 1 0 0	39 et food (Re 1 0 1 0 0	32 g.Exerci E 0 0 0 0	1.88 Go BP_Systol I 110 120 120 120 120	BP_Diasto 80 70 80 70	gs23,74 liv	ate 32/2 do	No Avg. F 3 5 5 2	18 15 18 15 16	1 2 1
1 0 IU/r LH(r 1.95 1.73 1.54	34 31 mIU/m H 3.68 1.09 0.88 2.36	57 58 dip(inch) 1 36 38 40 42	155 2 Waist(incl 30 32 36 36	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57	AMH(ng/m 2.07 1.53 6.63 1.22	72 PRL(ng/mL 45.16 20.09 10.52 36.9	18 Vit D3 (ng 17.1 61.3 49.7 33.4	10.5 / PRG(r 1 3 7 4	2 ng/ml RBS 0.57 0.97 0.36 0.36	i(mg/dl W 92 92 92 84 76	eight gai hair 0 0 0	0 growt Skin 0 0 0 0 0	darke Hai	2.8 ir loss(Y Pir 0 0 1	0.42 mples(Y/ Fas 0 0 1 0	39 at food (Re 1 0 1	32 g.Exerci E 0 0 0	1.88 Go	BP_Diastr 80 70 80	gs23,74 liv	ate 32/2 do	No Avg. F 3 5 5	18 15 18 15	1 2 1
1 0 U/r LH(r .95 i.73 i.54 i.06	34 31 mIU/m H 3.68 1.09 0.88 2.36 0.9	57 58 dip(inch) 3 36 38 40 42 37	155 2 Waist(incl 30 32 36 36	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6	AMH(ng/m 2.07 1.53 6.63 1.22 2.26	72 PRL(ng/mL 45.16 20.09 10.52 36.9 30.09	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8	10.5	2 0.57 0.97 0.36 0.36 0.38	92 92 84 76 84	eight gai hair 0 0 0	0 growt Skin 0 0 0 0 0 0	darke Hai	2.8 ir loss(Y Pir 0 0 1 0	0.42 mples(Y/ Fas 0 0 1 0 0	39 et food (Re 1 0 1 0 0	32 g.Exerci E 0 0 0 0	1.88 Go BP_Systol I 110 120 120 120 120	BP_Diasto 80 70 80 70	gs23,74 liv	o Follicle N	No Avg. F 3 5 5 2	18 15 18 15 16	1 1 2 1 1 2
1 0 U/r LH(r .95 .73 .54 .06	34 31 3.68 1.09 0.88 2.36 0.9 1.07	57 58 Hip(inch) 3 36 38 40 42 37 44	155 2  Waist(incl 30 32 36 36 30 38	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4	10.5	2 0.57 0.97 0.36 0.36 0.38	92 92 84 76 84 76	eight gai hair 0 0 0 0	growt Skin	0 darkei Hai 0 0 0 0	2.8 ir loss(Y Pir 0 0 1 0 1 1	0.42 mples(Y/ Fas 0 0 1 0 0 0	39 tt food (Re 1 0 1 0 0 0	32 g.Exerci E 0 0 0 0 0	1.88 Go  BP_Systol I  110  120  120  120  120  120  110	BP_Diasto 80 70 80 70	gs 23,74 iv.	ate 32/12 do	No Avg. F 3 5 5 5 2 4 6	18 15 18 15 16 16	1 1 2 1 1 2 1
1 0 0 1U/r LH(r .95 .73 .54 .06 .98 .24	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31	57 58 dip(inch) 1 36 38 40 42 37 44 39	155 2  Waist(incl 30 32 36 36 30 38 33	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7	10.5	2 0.57 0.97 0.36 0.36 0.38 0.3	92 92 92 84 76 84 76 93	eight gai hair 0 0 0 0 0	0 growt Skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darkei Hai 0 0 0 0	2.8 ir loss(Y Pir 0 0 0 1 0 1 1 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0	0.42 mples(Y/ Fas 0 0 1 0 0 0 0	39 at food (Re 1 0 1 0 0 0 0 0 0	32 g.Exerci E 0 0 0 0 0 0	1.88 Go  BP_Systol I  110  120  120  120  120  120  120  12	BP_Diasto 80 70 80 70 80 70 80	g 23.74 v	ate 3212 do	No Avg. F 3 5 5 2 4 6 6	18 15 18 15 16 16 16	1 2 1 1 2 1 1
1 0 0 U/r LH(r 1.95 i.73 i.54 i.06 i.98 i.24 i.85 i.86	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07	57 58 stip(inch) 1 36 38 40 42 37 44 39	155 2  Waist(incl 30 32 36 36 30 38 33 38	4.14152 hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.16 1.15 1.2.18 1.51	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38	10.5	2 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.26	92 92 84 76 84 76 93	eight gai hair 0 0 0 0 0 0	0 growt Skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darkei Hai	2.8 ir loss(Y Pir 0 0 0 1 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0	0.42 mples(Y/ Fas 0 0 1 0 0 0 0 0 0 0 0	39 Re 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	32 g.Exerci E 0 0 0 0 0 0 0	1.88 GO  SP_Systol I  110  120  120  120  120  120  120  12	BP_Diastal	gs 23.74 ivo	ate 3212 do	No Avg. F 3 5 5 5 2 4 6 6 6	18 15 18 15 16 16 15 15	1 2 1 1 2 1 1 1
1 0 0 U/r LH(r .95 i.73 i.54 i.06 i.98 i.24 i.85 i.86 i.76 i.28	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02	57 58 dip(inch) 1 36 38 40 42 37 44 39 44	155 2  Waist(incl 30 32 36 36 30 38 33 38 35 38	4.14152 hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 6.65	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7	10.5	2 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.26 0.3	92 92 92 84 76 84 76 93 91 116 125	eight gai hair 0 0 0 0 0 0	0 0 growt Skin 0 0 0 0 0 0 0	0 darke Hai	2.8  iir loss(Y Pir 0 0 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0	0.42  mples(Y/ Fas 0 0 1 0 0 0 0 0 0 0 0 0 0	39 et food Re 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	32 g.Exerci E 0 0 0 0 0 0 0 0 0	1.88 Go  BP_Systol II 110 120 120 120 120 120 120 120 120 120	BP_Diasts  80  70  80  70  80  70  80  80  80  80	gs 23.74 ivo	ate 3212 do	No Avg. F 3 5 5 5 2 4 6 6 6 6 6 7	18 15 18 15 16 16 15 15 15 17	1 1 2 1 1 2 1 1 1 1
1 0 0 U/r LH(r .95 i.73 i.54 i.06 i.98 i.24 i.85 i.86 i.76 i.28 i.89	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02	57 58 dip(inch) 1 36 38 40 42 37 44 39 44 49 40 39	155 2  Waist(incl 30 32 36 36 30 38 33 38 35	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 1.218 1.51 1.51	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7	10.5  // PRG(r 1 3 7 4 3 1 7 7 1 1	2 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.26 0.3 0.25	92 92 84 76 84 76 93 91 116 125	eight gai hair 0 0 0 0 0 0 1 0 0	0 o o o o o o o o o o o o o o o o o o o	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  ir loss(Y Pir 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0	0.42 mples(Y/ Fas 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0	39 at food (Re 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	32 g.Exerci E 0 0 0 0 0 0 0 0 0 0	1.88 GO  BP _Systol II  110  120  120  120  120  120  110  120  110  110  110  110	BP_Diasto 80 70 80 70 80 70 80 80 80 80 80 80 80	gs 23.74 iv.	ate 3212 do	No Avg. F 3 5 5 5 2 4 6 6 6 6 7 1	18 15 18 15 16 16 15 15 17 14	1 1 1 1 1 1 1 1 1
1 0 0 1 U/r LH(r95 173 154 106 1	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02	57 58 dip(inch) 1 36 38 40 42 37 44 39 44 39 40 39	155 2  Waist(incl 30 32 36 36 30 38 33 38 35 38 35	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.6.65 1.56 3.98	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 1.67	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1	Vit D3 (ng 17.1 61.3 49.7 33.4 42.7 38.8 21.8 27.7 18.1 29.18	10.5  / PRG(r 1 3 4 7 3 4 7 8 8 8 7 1 8 8 8 8 7 8 8 8 8 8 8 8 8 8	2 nng/ml RBS 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.36 0.25	92 92 84 76 84 76 93 91 116 125 108	eight gai hair 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0	0	0 darker Hai	2.8  ir loss(Y Pir 0 0 1 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0	0.42 mples(Y/ Fas 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	39 at food (Re 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	32 g.Exerci E 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  BP _Systol II  110  120  120  120  120  120  110  120  120  120  120  120  120  120  120  120  120  120  120  120  120	8P_Diaster 80 70 80 70 80 70 80 80 80 80 80 80 80 80 80 80 80 80	gs 23.74 iv.	o Follicle N	No Avg. F 3 5 5 5 2 4 6 6 6 6 7 1 1 5 2	18 15 18 15 16 16 15 15 17 14 17	1 1 1 1 1 1 1 1 1
1 0 0 1 U/r LH(r957354069824858676288909 2	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47	57 58 sip(inch) 1 36 38 40 42 37 44 39 44 39 40 39 40 39	155 2  Waist(incl 30 32 36 36 36 38 33 38 35 38 40	4.14152 hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 6.65 1.56 3.98 6.51	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 7.94	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7 18.1 29.18	10.5 PRG(s	2 nng/ml RBS 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.36 0.25 0.36	92 92 84 76 84 76 93 91 116 125 108 100	eight gai hair 0 0 0 0 0 0 1 0 1 0 0	0 Skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darkei Hai	2.8 ir loss(Y Pir 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0	0.42 mples(Y/ Fas 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 1 1 1	39 tt food   Re	32 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  P_Systol I  110  120  120  120  120  120  120  12	8P_Diastal 80 70 80 70 80 70 80 80 80 80 80 80 80 80 80 80 80 80 80	gs 23.74 iv.	o Follicle M	No Avg. F 3 5 5 5 5 2 4 4 6 6 6 6 6 7 7 1 1 5 2 2 8	18 15 18 15 16 16 15 15 17 14 17 18 20	
1 0 U/r LH(r .95 .73 .54 .06 .98 .24 .85 .76 .2.8 .89 .09 2 .84	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47 1.51	57 58 36 38 40 42 37 44 39 40 39 40 39	155 2  Waist(incl 30 32 36 36 36 30 38 33 38 35 38 35 38 35	4.14152 h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 6.65 1.56 3.98 6.51 1.48	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 7.94 2.38	72  PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43	18 Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7 18.1 29.18 31.4 21.2	10.5 PRG(s	2 ng/ml RBS 0.57 0.97 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.36 0.25 0.3	92 92 84 76 84 76 93 91 116 125 108 100 125 91	eight gai hair 0 0 0 0 1 0 0 0 1 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 1 0	0 Skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darkei Hai	2.8 iir loss(Y Pir 0 0 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0	0.42  mples(Y/ Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0	39 tt food   Re	32 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  P_Systol I  110  120  120  120  120  120  110  120  120  120  120  110  110  110  110  110  110  110  110  110  110  110  110  110	BP_Diasto 80 70 80 70 80 70 80 80 80 70 80 80 80 80 80 80 80 80 80	Follicle No. 3 3 13 2 2 3 9 6 7 5 1 1 7 4 4 15 3 3 3	ate 3212 do	No Avg. F 3 5 5 5 2 4 4 6 6 6 6 6 7 7 1 1 5 5 2 2	18 15 18 15 16 16 15 15 17 14 17 18 20 18	
1 0 U/r LH(r LH(r LH(r LH(r LH	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47 1.51 0.71 3.71	57 58 sip(inch) 1 36 38 40 42 37 44 39 40 39 40 39 39 39	155 2  Waist(incl 30 32 36 30 38 33 38 35 38 35 38 30 30 30	4.14152 hTSH (mIU/) 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.56 3.98 6.51 1.48 1.56	AMH(ng/m² 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 1.67 7.94 2.38 0.88	72 PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6	Vit D3 (ng 17.1 61.3 49.7 33.4 42.7 38 21.8 27.7 18.1 29.18 31.4 21.2 24.9	10.5 PRG(s	2 nng/ml RBS 0.57 0.97 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.36 0.25 0.3 0.4 0.26	(mg/dl W 92 92 84 76 93 91 116 125 91 116	eight gai hair 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darke Hai	2.8 iir loss(Y Pir 0 0 1 1 0 1 0 0 0 0 0 0 0 0 0 1 1 1 0 0 0 1 1 1 0 0 0 1 1 1 1 0 1 1 1 1 0 1	0.42  mples(Y/ Fas 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 1	39 at food Re 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1	32 g.Exerci E 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  P_Systol   110 120 120 120 120 120 120 120 120 120	BP_Diasto 80 70 80 70 80 70 80 80 70 80 80 70 80 80 80 80 80 80 80 80 80	9: 23.74 iv.	ate 3212 do	No Avg. F 3 5 5 5 4 6 6 6 6 7 1 1 5 5 2 2 4 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	18 15 18 15 16 16 15 15 17 14 17 18 20 18	
1 0 U/r LH(r S) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47 1.51 0.71 3.71	57 58 dip(inch) 1 36 38 40 42 37 44 39 44 39 40 39 45 39 45	155 2  Waist(incl 30 32 366 30 38 33 38 35 38 35 33 40 41	4.14152 hTSH (mIU/ 0.68 3.16 2.54 1.64 3.57 1.6 1.51 1.51 6.65 1.56 3.98 6.51 1.48 1.51 1.48	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 1.67 7.94 2.38 0.88 0.69	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6 92.65	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7 18.1 29.18 31.4 21.2 24.9	10.5 / PRG(s	2 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.36 0.25 0.36 0.25	92 92 84 76 84 76 93 91 116 125 108 100 125 91 116	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 1 0 1	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0  darke Hai  0  0  0  0  0  0  0  0  0  0  0  0  0	2.8 iir loss(Y Pir 0 0 1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0	0.42 mples(Y/ Fas 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	39  t food (Re 1 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 1 0	32 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  BP _Systol I 110	BP_Diasts  80  70  80  80  70  80  80  80  80  80	Follicle No. 3 3 3 3 3 9 6 6 7 7 5 5 1 1 7 4 4 1 5 3 4 4 1 1 1	ate 32i2 do	No Avg. F 3 5 5 5 2 4 4 6 6 6 6 7 1 1 1 5 5 2 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	18 15 18 15 16 16 15 15 17 14 17 18 20 18 19	
1 0 U/r LH(r S) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47 1.51 0.71 3.71	57 58 36 38 40 42 37 44 39 40 39 45 39 38	155 2  Waist(incl 30 32 36 30 38 33 38 35 38 35 38 30 30 30	4.14152  hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 1.158 1.58 1.59 1.56 1.56 1.56 1.56 1.56 1.56 1.58 1.58 1.98	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 7.94 2.38 0.88 0.69 3.78	72 PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6	Vit D3 (ng 17.1 61.3 49.7 33.4 42.7 38 21.8 27.7 18.1 29.18 31.4 21.2 24.9	10.5 / PRG(s	2 nng/ml RBS 0.57 0.97 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.36 0.25 0.3 0.4 0.26	(mg/dl W 92 92 84 76 93 91 116 125 91 116	eight gai hair 0 0 0 0 0 1 0 1 0 0 0 1 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darke Hai	2.8  ir loss(Y Pir 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 1 1 0	0.42  mples(Y/ Fas 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 1 1 0 1 1	39 at food Re 1 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 1	32 g.Exerci E 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  P_Systol   110 120 120 120 120 120 120 120 120 120	BP_Diasts  BP_Diasts  80  80  70  80  70  80  80  80  80  80	gs 23,74 iv.	D Follicle N	No Avg. F 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	18 15 18 15 16 16 15 17 14 17 18 20 18 19 14 20	
1 0 U/r LH(r S) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	34 31 31 3.68 1.09 0.88 2.36 0.9 0.31 3.07 3.02 1.51 0.71 3.71 1.51 0.71 2.51 0.65 2.96	57 58 dip(inch) 1 36 38 40 42 37 44 39 40 39 40 39 45 39 38 44 39 45 39	155 2  Waist(incl 30 32 36 36 30 38 33 38 35 38 40 33 30 41 29	4.14152  h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 6.655 1.56 3.98 6.51 1.48 1.18 1.98	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 1.67 7.94 2.38 0.88 0.69	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6 92.65 20.25	Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7 18.1 29.18 31.4 21.2 24.9	10.5 // PRG(s) l l l l l l l l l l l l l l l l l l l	2 0.57 0.97 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.3 0.45 0.25 0.3 0.4 0.25	92 84 76 84 76 84 76 93 91 116 125 100 125 91 116 116 116	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 1 1 0 1 0 1 1 1 0 1 1 1 0 1 1 1 0 1 1 1 1 0 1	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0  darke Hai  0  0  0  0  0  0  0  0  0  0  0  0  0	2.8  ir loss(Y Pir 0 0 1 1 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0	0.42  mples(Y/Fas 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0	39  t food (Re 1 0 0 0 0 0 0 0 0 0 1 1 0 0 1 0 0 0 1 0	32 B. Exerci E 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  P _ Systol # 110 120 120 120 120 120 120 110 120 120	BP_Diasts 80 70 80 70 80 70 80 80 80 80 80 80 80 80 80 80 80 80 80	gs 23.74 iv.	o Follicle N	ows 0.52  No Avg. F  5  5  6  6  6  7  1  1  5  2  8  3  1  3  5  2  8	18 15 18 15 16 16 15 17 14 17 18 20 18 19 14 20 20	
1 0 1 1 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47 1.51 0.71 3.71	57 58 36 38 40 42 37 44 39 40 39 45 39 38	155 2  Waist(incl 30 32 366 30 38 33 38 35 38 35 38 40 41 29	4.14152  h TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 6.655 1.56 3.98 6.51 1.48 1.18 1.98	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 7.94 2.38 0.88 0.69 3.78	72 PRL(ng/mL 45.16 20.09 10.52 36.99 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6 92.65 20.25	18 Vit D3 (ng 17.1 61.3 49.7 33.4 42.7 38 21.8 21.8 21.2 29.18 31.4 21.2 9.7 7 19.1 19.1 19.1 19.1 19.1 19.1 19.	10.5 // PRG(s) l l l l l l l l l l l l l l l l l l l	2 nsg/ml RBS 0.57 0.97 0.97 0.36 0.36 0.38 0.3 0.46 0.25 0.3 0.25 0.3 0.4 0.25 0.3 0.4 0.26 0.3 0.46	92 92 92 84 76 84 76 93 91 116 125 108 100 125 91 116 116	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0	0 growt Skin 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darke Hai	2.8  ir loss(Y Pir 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 1 1 0	0.42  mples(Y/Fas 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 0 0 0 0	39  tt food   Re 1 0 0 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0	32 g.Exerci E 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  BP _Systol I 110	BP_Diasts  BP_Diasts  80  80  70  80  70  80  80  80  80  80	gs 23.74 iv.	o Follicle N	No Avg. F 3 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	18 15 18 15 16 16 15 17 14 17 18 20 18 19 14 20	
1 0 U/r LH(r LH(r LH(r LH(r LH(r LH(r LH(r LH(	34 31 31 3.68 1.09 0.88 2.36 0.9 0.31 3.07 3.02 1.51 0.71 3.71 1.51 0.71 2.51 0.65 2.96	57 58 dip(inch) 1 36 38 40 42 37 44 39 40 39 40 39 45 39 38 44 39 45 39	155 2  Waist(incl 30 32 36 36 30 38 33 38 35 38 40 33 30 41 29	4.14152 hTSH (mIU/) 0.68 3.16 2.54 16.41 3.57 1.66 1.51 12.18 1.51 1.56 1.56 1.56 1.51 1.18 1.98 1.51 1.18	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 1.67 7.94 2.38 0.88 0.69 3.78 1.92	PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6 92.65 20.25	18 Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 21.8 27.7 38.1 29.18 31.4 21.2 24.9 9.7 19.1 26	10.5 PRG(t)  1 P	2 0.57 0.97 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.3 0.45 0.25 0.3 0.4 0.25	92 84 76 84 76 84 76 93 91 116 125 100 125 91 116 116 116	eight gai hair 0 0 0 0 0 0 1 0 0 0 1 0 0 0 0 1 0 0 0 0 1 0	0 growt Skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 darkei Hai	2.8  ir loss(Y Pir 0 0 1 1 0 0 1 1 0 0 0 1 1 1 0 0 0 1 1 0	0.42  mples(Y/Fas 0 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0	39  t food (Re 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 0 0	32 B. Exerci E 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  P _ Systol # 110 120 120 120 120 120 120 110 120 120	BP_Diasts 80 70 80 70 80 70 80 80 80 80 80 80 80 80 80 80 80 80 80	9 23,74 v.	o Follicle N	ows 0.52  No Avg. F  5  5  6  6  6  7  1  1  5  2  8  3  1  3  5  2  8	18 15 18 15 16 16 15 17 14 17 18 20 18 19 14 20 20	
1 0 U/r LH(r LH(r 14) 15 15 15 15 15 15 15 15 15 15 15 15 15	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 1.51 2.02 1.51 0.71 3.71 2.51 0.65 0.65	57 58 dip(inch) 1 36 38 40 42 37 44 39 40 39 40 39 45 39 44 39 39 45 39 39 39 47 48 39 39 49 40 39 39 40 39 40 40 40 40 40 40 40 40 40 40 40 40 40	155 2  Waist(incl.) 30 36 36 36 37 38 38 35 38 35 38 35 38 37 38 38 38 38 38 38 38 38 38 38 38 38 38	4.14152 hTSH (mIU/) 0.68 3.16 2.54 16.41 3.57 1.66 1.51 1.51 6.65 1.56 3.98 1.51 1.48 1.51 1.18 1.98 5 3.19	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.055 1.54 1 1.61 4.47 1.67 7.94 2.38 0.69 3.78 1.78 1.78 1.78 1.78 1.78 1.78 1.78 1	72 PRL(ng/mL' 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.65 20.25 12.52 12.05	18 Vit D3 (ng 17.1 61.3 49.7 33.4 43.8 52.4 42.7 38 21.8 27.7 18.1 29.18 31.4 21.2 24.9 9.7 12.6 23.3	10.5 PRG(s) PRG(s) 10.5 PRG(s)	2 ng/ml RBS 0.57 0.97 0.36 0.36 0.38 0.3 0.46 0.25 0.36 0.25 0.36 0.25 0.36 0.25 0.30 0.4 0.26 0.3 0.40 0.26 0.3 0.40 0.26 0.3 0.40 0.26 0.3 0.40 0.25 0.3	92 84 76 84 76 84 76 116 125 108 100 125 91 116 116 116 116 116 117 117 118 119 119 110 110 110 110 110 110 110 110	eight gai hair 0 0 0 0 0 1 0 1 0 0 1 0 0 1 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  iir loss(Y Pir 0 0 0 1 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0	0.42  nples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0	39  It food (Re 1 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0	32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go  SP_Systol I 110 120 120 120 120 120 120 120 120 120	BP_Diastr 80 70 80 70 80 70 80 80 80 80 80 80 80 80 80 80 80 80 80	gs 23,74 iv.	p Follicle N	0.52 Avg. F 3 3 3 5 5 5 5 2 2 4 4 6 6 6 6 6 6 7 7 1 1 5 5 5 5 2 2 8 8 3 3 1 1 3 3 5 5 5 5 2 2 2 2 2 2	18 15 18 15 16 16 15 17 14 17 18 20 18 19 14 20 0	
1 0 0	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 3.02 1.51 2.02 1.47 1.51 0.71 3.71 2.51 0.65 2.96 1.05 0.81	57 58 36 36 38 40 42 42 43 39 44 39 39 39 39 38 44 46 39 39 38 48 44 40 39 39 38 48 40 40 40 40 40 40 40 40 40 40 40 40 40	155 2  Waist(included) 30 32 36 36 36 38 38 38 35 38 40 40 29 32 33 30 40 41 42 42 44	4.14152 hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 6.65 3.98 6.51 1.48 1.51 1.	AMH(ng/m 2.07 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 1.67 7.94 8.0 6.88 0.69 3.78 1.92 1 2.07 2.85	72 PRL(ng/mL' 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19 11.74 13.47 21.1 22.43 15.62 19.6 92.65 20.25 12.52 12.52 19.53 19.53 19.53 19.54 19.55	18 17.1.1 17.1 17.1 17.1 17.1 17.1 17.1	10.5 PRG(n 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2 0.057 0.97 0.97 0.96 0.38 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.25 0.3 0.46 0.25 0.25 0.3 0.46 0.25 0.25 0.25 0.25 0.3 0.46 0.25 0.25 0.25 0.25 0.3 0.4 0.4 0.25 0.25 0.25 0.25 0.25 0.3 0.4 0.4 0.25 0.25 0.25 0.3 0.4 0.4 0.4 0.25 0.25 0.25 0.3 0.4 0.4 0.4 0.25 0.25 0.25 0.3 0.4 0.4 0.4 0.25 0.3 0.4 0.4 0.25 0.3 0.4 0.4 0.25 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.3 0.3 0.4 0.2 0.3 0.3 0.4 0.4 0.2 0.2 0.3 0.3 0.4 0.4 0.2 0.2 0.3 0.3 0.4 0.2 0.3 0.4 0.2 0.2 0.3 0.3 0.4 0.2 0.2 0.2 0.3 0.3 0.4 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	92 84 76 93 91 116 125 100 125 91 116 91 100 91	eight gai hair 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  ir loss(Y Pir 0 0 0 1 1 1 0 0 0 0 0 0 1 1 0 0 0 0 0	0.42  mples(Y/Fas 0 0 0 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0	39 at food Re 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 GO  P Systol I 110 120 120 120 120 120 120 120 120 120	BP_Diastitude	9 23.74 w	D Follicle N	No Avg. F  No Avg. F  S  S  S  S  S  S  S  S  S  S  S  S  S	18 15 18 15 16 16 16 15 17 14 17 18 20 18 19 14 20 20 0 18 18 18	
1 0 0 UU/r LH(r 10 10 10 10 10 10 10 10 10 10 10 10 10	34 31 3.68 1.09 0.9 1.07 0.31 3.07 3.02 1.47 1.51 2.02 1.47 1.51 2.02 1.47 1.51 2.02 1.47 1.51 2.02 1.07 0.71 3.71 2.51 3.61 3.71 3.71 3.71 3.71 3.71 3.71 3.71 3.7	57 58 36 38 40 42 37 44 39 40 39 40 39 45 39 45 39 45 49 40 49 40 40 40 40 40 40 40 40 40 40 40 40 40	155 2  Waist(incl.) 30 32 36 36 36 38 33 38 35 35 33 30 41 29 32 33 42 29	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.66 1.51 1.218 1.51 6.655 1.56 3.98 1.51 1.48 1.98 1.98 5.31 3.198 5.51	AMH(ng/m 2.07 1.53 1.22 2.26 6.74 3.05 1.54 1 1.61 4.47 7.94 2.38 0.69 3.78 1.92 1 2.07 2.85 2.13	72 PRL(ng/mL 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 19.174 13.47 21.1 22.43 15.62 19.65 20.25 12.52 12.52 12.05 19.13 33.62 40.74	18 17.1 17.1 18.5 18.5 18.5 18.5 18.5 18.5 18.5 18	10.5 PRG(n l l l l l l l l l l l l l l l l l l l	2 ng/ml RBS 0.057 0.97 0.36 0.38 0.3 0.46 0.25 0.36 0.25 0.3 0.44 0.26 0.3 0.25 0.3 0.44 0.26 0.3 0.25 0.3 0.44 0.26 0.3 0.3 0.44 0.3 0.40 0.25 0.3 0.44 0.3 0.40 0.3 0.45 0.25 0.3 0.40 0.25 0.3 0.40 0.3 0.40 0.3 0.40 0.3	(mg/dl W 92 92 92 84 76 84 76 93 91 116 125 91 116 116 127 100 127 100 84 84 84 84 84 84 84 84 84 84 84 84 84	eight gai hair 0 0 0 0 0 1 0 0 1 0 0 0 1 0 0 0 1 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0  darkei Hai  0  0  0  0  0  0  0  0  0  0  0  0  0	2.8  iir loss(Y Pir 0 0 1 1 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 1 1 0	39  It food   Re 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 1 1 0 1 1 1 0 0 1	32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 GoV Systol of 1100 1120 1200 1200 1200 1200 1200 120	BP_Diasts14in  BP_Diasts14in  80  70  80  70  80  80  80  80  80  80	Follicle No. 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3	D Follicle N	No Avg. F 5 5 5 5 5 2 2 2 4 8 8 3 3 1 1 3 3 5 5 5 2 2 2 2 8 8 8 2 2 2 2 2	18 15 18 15 16 16 16 15 17 14 17 18 20 18 19 14 20 0 18 18 18 17	
1 0 0 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1	34 31 3.68 1.09 9.09 1.07 0.31 3.07 3.02 1.51 2.02 1.47 1.51 2.02 1.47 1.51 2.02 1.47 1.51 2.02 1.07 3.71 2.51 3.71 2.51 3.71 3.71 3.71 3.71 3.71 3.71 3.71 3.7	57 58 366 40 42 23 37 44 39 40 39 40 43 49 40 39 40 40 40 40 40 40 40 40 40 40	155 2  Waist(included) 30 32 36 36 38 38 38 35 38 40 41 29 32 34 42 34 34 33 34	4.14152 hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 1.51 6.65 1.56 3.98 6.51 1.18 1.18 1.98 5 3.19 2.87 1.86 5 3.19	15  AMH(ng/m 2.07 1.53 3.05 1.22 2.26 2.6 1.22 1.26 1.22 1.26 1.27 1.26 1.27 1.26 1.27 1.26 1.26 1.26 1.26 1.26 1.26 1.26 1.26	72 45.16 20.09 10.52 36.9 30.09 16.18 26.41 3.97 21.1 13.47 21.1 22.43 15.62 19.6 92.65 20.25 12.52 12.52 12.52 12.52 12.53 13.62 40.74 40.	18   17.1   17.1   18.2	10.5 PRG(a)	2 neg/mi RBS 0.57 0.97 0.36 0.38 0.3 0.25 0.33 0.46 0.225 0.3 0.46 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.3 0.25 0.25 0.25 0.3 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.3 0.25 0.25 0.25 0.25 0.25 0.25 0.3 0.25 0.25 0.25 0.25 0.25 0.25 0.25 0.25	(mg/dl W 92 92 92 84 76 93 116 125 91 116 116 116 116 110 100 127 100 91 84 116	eight gai hair 0 0 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  2.8  0  0  0  1  1  0  0  0  0  1  1  0  0	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 1 1 0	39 39 11 to food   Ree 1	32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 George Systol of 110 120 120 120 120 120 120 120 120 120	District	Follicle No. 7 Follic	32/2 doc	NO Avg. F 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	18 15 18 15 16 16 16 15 17 14 17 18 20 20 0 18 18 18 17 16 16 16 17 18 18 19 11 17 17 18 18 19 11 11 11 11 11 11 11 11 11 11 11 11	
1 0 U/r LH(r LH(r LH(r LH(r LH(r LH(r LH(r LH(	34 31 3.68 1.09 0.88 2.36 0.9 0.31 3.07 0.31 5.02 1.51 0.71 3.71 0.65 2.96 1.05 0.90 1.07 0.31 3.07 1.51 0.51 0.51 0.51 0.51 0.51 0.51 0.51	57 58 36 40 42 44 39 40 40 39 39 40 40 43 49 40 40 41 42 43 49 40 40 40 41 41 42 42 43 44 44 43 49 40 40 40 40 40 40 40 40 40 40 40 40 40	155 2  Waist(included and a second a second and a second and a second a second and a second a second and a second a second and a second a second and	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 1.56 1.56 1.56 1.56 1.51 1.18 1.98 1.98 1.98 1.98 1.98 1.98 1.9	15 AMH(ng/n² 207) 1.53 6.63 1.22 2.26 6.74 3.05 1.54 1.1.61 1.61 1.67 1.94 1.67 1.94 1.67 1.94 1.67 1.94 1.67 1.94 1.67 1.94 1.92 1.92 1.92 1.92 1.93 1.92 1.93 1.93 1.93 1.93 1.93 1.93 1.93 1.93	72 PRL[ng/ml 45.16 45.16 20.52 36.9 36.9 10.18 26.41 3.97 11.74 21.17 22.43 11.74 21.17 22.43 11.33 33.62 40.74 40.74 13.38 17.88	18 17.1 17.1 18.1 18.1 18.1 18.1 18.1 18	10.5 PRG(s)	2 nng/mi RBS 0.0.57 0.97 0.97 0.97 0.36 0.36 0.38 0.3 0.46 0.26 0.3 0.25 0.35 0.4 0.26 0.3 0.4 0.26 0.3 0.4 0.26 0.3 0.4 0.26 0.3 0.4 0.26 0.7 0.3 0.4 0.26 0.7 0.3 0.4 0.2 0.3 0.4 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.4 0.3 0.2 0.2 0.3 0.3 0.4 0.3 0.2 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.4 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3 0.3	(mg/dl W 92 92 92 84 76 93 116 125 108 116 116 91 110 100 91 84 116 92 92	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 1 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8 iri loss[Y Pir loss[Y Pir loss]	0.42  mples(Y/Fas 0 0 1 0 0 0 0 0 0 0 0 0 1 0 0 0 0 0 0	39  1 t food (Re food of Re food	32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Gold   1.89 Systol   110   110   120	BP_Diasts   10   10   2   34   in   10   10   2   34   in   10   10   2   34   in   10   10   10   10   10   10   10   1	Follicle N. Follic	32/2 doc	No Avg. F 3 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	18 15 18 15 16 16 16 15 17 14 17 18 20 18 19 14 20 0 18 18 17 16 14 17	
1 0 0 UU/r LH(r 14) 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	34 31 mIU/m H 3.68 2.36 0.9 1.07 0.31 2.02 1.51 2.02 1.47 7.51 1.65 0.65 0.81 1.3 2.18 2.3 2.3 2.3 3.0 3.0 3.0 3.0 3.0 3.0 3.0 3	57 58 36 38 40 42 37 44 43 99 45 39 39 44 36 36 37 38 8	155 2  Waist(included and a second a second and a second	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.66 1.51 1.68 1.51 1.51 1.51 1.51 1.51 1.58 1.59 1.58 1.59 1.59 1.59 1.59 1.59 1.59 1.59 1.59	15 AMH(ng/n² 2.07 2.07 1.53 6.63 1.22 2.66 6.74 1.55 1.54 1.54 1.54 1.54 1.66 1.54 1.54 1.67 1.67 1.67 1.67 1.67 1.67 1.67 1.67	72 PRL[ng/ml 45.16 20.99 10.52 36.99 16.18 26.41 13.47 21.1 11.74 11	18 (17.17.18.18.18.18.18.18.18.18.18.18.18.18.18.	10.5 PRG(a)  1 PRG(a)  1 PRG(b)  1 P	2 nsg/ml RBS 0.57 0.97 0.97 0.97 0.96 0.36 0.36 0.36 0.26 0.26 0.3 0.25 0.36 0.25 0.3 0.25 0.3 0.4 0.25 0.3 0.4 0.26 0.3 0.25 0.3 0.4 0.26 0.3 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.25 0.3 0.26 0.4 0.3 0.26 0.3 0.26 0.3 0.26 0.3 0.26 0.3 0.26 0.25 0.3 0.26 0.2 0.2 0.3 0.26 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2 0.2	(mg/dl W 92 92 92 84 476 84 76 116 116 116 116 116 116 116 116 116	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  2.8  ir loss(Y Pir loss) 0 0 0 1 1 0 0 0 0 0 1 1 0 0 0 0 0 0 1 1 0	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 1 1 0 1 1 0 1 1 0 1 1 1 0 1 1 1 1 0 1	39  1 t food (Ref food) 0 t food) 0 t food) 1 t food) 0 t food) 0 t food) 1 t food) 0 t food) 0 t food) 1 t food) 0 t food) 0 t food) 1	32 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go	District	C Follicle No. 7 Foll	52.2 do Follicle N	No Avg. F 3 3 5 5 5 5 2 4 4 6 6 6 6 6 7 7 1 1 5 5 5 2 2 2 2 2 2 2 7 7 8 8 8 6 6	18   15   16   16   16   15   17   14   17   18   20   18   19   14   20   20   0   18   18   17   16   14   17   18   19   19   10   11   11   11   11   11	
1 0 U/r LH(r) LH(r	34 31 3.68 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 2.05 0.71 1.51 0.65 2.96 0.88 1.3 3.71 2.51 0.65 2.96 0.88 1.05	57 58 37 58 38 38 40 40 42 37 44 39 40 39 45 39 45 39 45 39 45 39 46 39 47 39 48 49 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 30 40 30 30 30 30 30 30 30 30 30 30 30 30 30	155 2  Waist(included and and and and and and and and and an	4.14152 hTSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 1.51 6.65 1.56 3.98 6.51 1.18 1.98 5 3.19 2.87 1.86 5.71 1.86 5.71 1.26 5.71 1.26 5.71 5.71 5.71 5.71 5.71 5.71 5.71 5.71	15  AMH(ng/n² - 2.07  2.07  1.53  6.63  1.22  6.674  3.05  6.74  1.61  1.61  1.67  7.94  4.47  1.67  7.94  2.38  0.88  1.92  1.02  2.02  2.03  3.03  3.03  4.13  4.43  4.44  4.44  4.47  1.67  4.44  4.44  4	72 PRL[ng/ml 45.16 45.16 20.09 10.52 36.99 16.18 26.41 13.47 21.1 22.43 15.62 19.6 26.55 12.52 12.05 12.13 33.62 40.74 11.46 11.46 11.48 11.48	18 (17.1 ) 18 (18.1 )	10.5 / PRG(i	2 ng/mi RBS 0.57 0.97 0.97 0.97 0.36 0.38 0.38 0.38 0.25 0.36 0.25 0.36 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.49 0.98 0.98 0.98	(mg/dl W 92 92 92 92 92 92 92 92 92 92 92 92 92	Geight gai hair  O O O O O O O O O O O O O O O O O O	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8 iir loss(Y Piri source of the control of the co	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0	39  1 food   Re   1	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 George 1.88 George 1.88 George 1.88 George 1.89 George 1.80 G	BP_Diasts	Follicle No. 7 Follic	D Follicle N	No Avg. F S S S S S S S S S S S S S S S S S S	18	
1 0 0 U/r LH(r 14 14 14 14 14 14 14 14 14 14 14 14 14	34 31 3.68 1.09 0.88 2.36 0.9 1.07 3.02 1.51 2.02 1.47 1.51 2.51 1.05 2.96 1.05 2.96 1.07 3.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.08 3.08	57 58 36 38 40 42 37 44 43 99 45 39 39 45 39 37 44 36 36 37 37 38 39 36 37 38 39 36 37 38	155 2  Waist(included) 30 32 36 36 36 38 38 38 35 35 39 40 41 41 29 9 32 32 32 32 32	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 12.18 1.51 1.56 3.98 1.51 1.48 1.51 1.98 1.51 1.18 1.98 1.51 1.18 1.98 1.51 1.08 1.06 1.51 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.0	15 AMH(ng/m 2.07 2.07 1.53 6.63 1.22 2.26 6.74 1.53 1.55 1.54 1.67 1.67 1.67 1.67 1.67 1.67 1.67 1.67	72 PRL[ng/ml 45.16 20.99 10.52 36.99 10.52 36.99 10.52 30.99 11.74 13.47 11.74 13.47 19.6 20.25 20.25 19.3 40.74 13.88 11.46 17.38 17.88 11.46 17.18	18 (17.17.18.18.18.18.18.18.18.18.18.18.18.18.18.	10.5 / PRG(i	2 nng/ml RBS 0.57 0.36 0.36 0.36 0.36 0.32 0.36 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.40 0.26 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35	(mg/dl W 92 92 92 92 92 92 92 92 92 92 92 92 92	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 1 1 0	0  growt Skin	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  2.8  0  0  1  0  1  1  0  0  0  1  1  0  0	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	39  1 t food (Re food) (Re	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go	BP_Diasts   Diasts	G 523.74bw	D Follicle N	0.52 No Avg. F 3 3 5 5 5 5 5 2 2 4 4 6 6 6 6 6 7 7 1 1 1 1 5 5 2 2 8 8 8 3 3 1 5 5 5 2 2 2 8 8 8 2 2 2 2 7 7 8 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	18   15   16   16   15   17   18   19   10   10   11   11   11   11   11	
1 0 U/r LH(r LH(r LH(r LH(r LH(r LH(r LH(r LH(	34 31 3.68 2.36 0.9 1.07 0.31 3.07 3.02 1.51 2.02 2.05 0.71 1.51 0.65 2.96 0.88 1.3 3.71 2.51 0.65 2.96 0.88 1.05	57 58 37 58 38 38 40 40 42 37 44 39 40 39 45 39 45 39 45 39 45 39 46 39 47 39 48 49 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 30 40 30 30 30 30 30 30 30 30 30 30 30 30 30	155 2  Waist(included and and and and and and and and and an	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 1.56 3.98 1.51 1.18 1.98 1.51 1.18 1.98 1.51 1.18 1.98 1.51 1.18 1.98 1.00 1.00 1.00 1.00 1.00 1.00 1.00 1.0	15  AMH(ng/n² - 2.07  2.07  1.53  6.63  1.22  6.674  3.05  6.74  1.61  1.61  1.67  7.94  4.47  1.67  7.94  2.38  0.88  1.92  1.02  2.02  2.03  3.03  3.03  4.13  4.43  4.44  4.44  4.47  1.67  4.44  4.44  4	72 PRL[ng/ml 45.16 45.16 20.09 10.52 36.99 16.18 26.41 13.47 21.1 22.43 15.62 19.6 26.55 12.52 12.05 12.13 33.62 40.74 11.46 11.46 11.48 11.48	18 (17.1 ) 18 (18.1 )	10.5 / PRG(i	2 ng/mi RBS 0.57 0.97 0.97 0.97 0.36 0.38 0.38 0.38 0.25 0.36 0.25 0.36 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.49 0.98 0.98 0.98	(mg/dl W 92 92 92 92 92 92 92 92 92 92 92 92 92	Geight gai hair  O O O O O O O O O O O O O O O O O O	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8 iir loss(Y Piri source of the control of the co	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0	39  1 food   Re   1	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 George 1.88 George 1.88 George 1.88 George 1.89 George 1.80 G	BP_Diasts	G 523.74bw	D Follicle N	No Avg. F S S S S S S S S S S S S S S S S S S	18	11 11 11 11 11 11 11 11 11 11 11 11 11
1 0 0 UU/r LH(r 10 10 10 10 10 10 10 10 10 10 10 10 10	34 31 3.68 1.09 0.88 2.36 0.9 1.07 3.02 1.51 2.02 1.47 1.51 2.51 1.05 2.96 1.05 2.96 1.07 3.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.02 1.07 3.08 3.08	57 58 36 38 40 42 37 44 43 99 45 39 39 45 39 37 44 36 36 37 37 38 39 36 37 38 39 36 37 38	155 2  Waist(included) 30 32 36 36 36 38 38 38 35 35 39 40 41 41 29 9 32 32 32 32 32	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.66 1.51 1.51 1.51 1.51 1.51 1.51 1.52 1.55 1.56 1.56 1.56 1.56 1.56 1.56 1.56	15 AMH(ng/m 2.07 2.07 1.53 6.63 1.22 2.26 6.74 1.53 1.55 1.54 1.67 1.67 1.67 1.67 1.67 1.67 1.67 1.67	72 PRL[ng/ml 45.16 20.99 10.52 36.99 10.52 36.99 10.52 30.99 11.74 13.47 11.74 13.47 19.6 20.25 20.25 19.3 40.74 13.88 11.46 17.38 17.88 11.46 17.18	18 (17.17.18.18.18.18.18.18.18.18.18.18.18.18.18.	10.5 PRG(i	2 nng/ml RBS 0.57 0.36 0.36 0.36 0.36 0.32 0.36 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.46 0.25 0.3 0.40 0.26 0.35 0.35 0.35 0.35 0.35 0.35 0.35 0.35	(mg/dl W 92 92 92 92 92 92 92 92 92 92 92 92 92	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 1 0 0 0 1 1 0 0 0 0 0 0 0 0 0 0 0 1 1 0 0 0 0 1 1 0 0 0 1 1 0 0 0 0 1 1 0 0 0 0 1 1 0	0  growt Skin	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  2.8  0  0  1  0  1  1  0  0  0  1  1  0  0	0.42  mples(Y/Fas 0 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	39  1 t food (Re food) (Re	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Go	BP_Diasts   Diasts	C Follicle No. 7 Foll	D Follicle N	0.52 No Avg. F 3 3 5 5 5 5 5 2 2 4 4 6 6 6 6 6 7 7 1 1 1 1 5 5 2 2 8 8 8 3 3 1 5 5 5 2 2 2 8 8 8 2 2 2 2 7 7 8 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	18   15   16   16   15   17   18   19   10   10   11   11   11   11   11	1 1 1 2 1 1 1 1 1 2 2 2 2 2 2 1 1 1 1 1
1 0 0 UJ/r LH(r 14) 1 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0	34 31 mIU/m H 5.68 1.09 0.88 8.236 0.9 1.07 0.31 3.07 3.02 1.51 2.02 1.47 0.71 3.71 0.65 2.96 0.81 1.05 0.88 1.09 0.88 4.39 0.88 4.39 0.88 0.89 0.88 0.89 0.88 0.89 0.88 0.89 0.89	57 58 36 38 38 38 40 42 37 44 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 39 40 40 39 40 40 40 39 40 40 40 40 40 40 40 40 40 40 40 40 40	155 2 304Waist(inclass) 30 32 33 34 35 35 35 36 36 36 37 37 37 37 37 37 37 37 37 37 37 37 37	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.6 1.51 12.18 1.51 1.6.65 1.56 1.56 1.56 1.58 1.51 1.18 1.18 1.98 1.98 1.51 1.18 1.98 1.98 1.51 1.18 1.98 1.98 1.98 1.91 1.18 1.98 1.9	15 AMH(ng/n² 2.07 2.07 1.53 6.63 1.122 2.66 6.74 1 1.51 1.54 1.54 1.55 1.54 1.54 1.55 1.54 1.54	72 PRL[ng/ml 45.16 20.99 10.52 36.99 16.18 26.41 13.47 11.47 21.1 12.43 22.63 20.25 19.66 20.25 19.13 33.62 40.41 13.47 14.41 15.42 17.43 18.42 19.43 19.44 19	18 Vit D3 (ngg 26 12 12 12 12 12 12 12 12 12 12 12 12 12	10.5 PRG(n	2 ng/mi RBS 0.57 0.36 0.36 0.38 0.36 0.25 0.36 0.38 0.25 0.36 0.25 0.36 0.46 0.25 0.35 0.46 0.25 0.37 0.46 0.3 0.35 0.25 0.3 0.3 0.35 0.35 0.35 0.35 0.35 0.35	(mg/dl w. 92 92 92 84 76 84 76 93 91 116 125 108 116 116 116 116 91 100 127 100 92 100 92 100 92 100 92	eight gai hair 0 0 0 0 0 1 0 0 1 0 0 0 0 1 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  ir loss(Y Pir los) 0 0 1 1 0 0 0 0 0 0 0 1 1 0 0 0 0 0 0	0.42  mples(Y/Fas 0 0 0 0 1 0 0 0 0 0 0 0 0 0 0 1 0 0 0 1 0 0 0 1 0 0 1 0 0 0 1 0 0 0 0 1 0	39  1 t food   Re   1	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Gold   1.88 Gold   1.00	BP_Diasts BP_Dia	g 23.74 lw F Follicle No. 2 F Follicle N	32/2 do	0.52 No Avg. F S S S S S S S S S S S S S S S S S S	18   15   16   16   17   18   18   18   19   10   11   11   11   11   11   11	14 22 20 14 15 15 16 16 16 16 16 16 16 16 16 16 16 16 16
1 0 0 U/r LH(r LH(r LH(r LH(r LH(r LH(r LH(r LH(	34 31 3.68 1.09 0.88 2.36 0.9 1.07 0.31 1.51 2.02 1.47 1.51 2.07 1.51 2.07 1.51 2.01 1.05 2.96 0.81 1.3 1.09	57 58 37 58 38 38 40 42 37 44 49 39 40 39 45 39 45 39 45 39 37 38 38 39 37 37 38 49 40 40 40 40 40 40 40 40 40 40 40 40 40	155 2  Waist(included and and and and and and and and and an	4.14152  TSH (mIU/ 0.68 3.16 2.54 16.41 3.57 1.66 1.51 12.18 1.51 1.56 3.98 1.51 1.48 1.51 1.98 1.51 1.18 1.98 1.51 1.98 1.98 1.51 1.98 1.98 1.98 1.98 1.98 1.98 1.98 1.9	15  AMH(ng/m 2.07  2.07  1.53  6.63  6.74  1.53  3.05  1.54  1.61  4.47  1.67  7.94	72  PRL[ng/ml 45.16 45.16 20.99 10.52 36.99 10.52 36.99 10.52 36.99 16.18 3.97 19 11.74 13.47 21.1 13.47 21.1 13.47 21.1 13.47 21.1 13.47 15.62 20.55 19.66 11.74 13.75 17.88 17.88 17.88 17.88 17.88 17.88 17.88 17.88	18 Vit D3 (ng ng 17.7.) 13.44 49.9.34 44.7.42 45.61 18.16 19.97 19.16 19	10.5 PRG(n)  1 P	2 2 5 6 7 7 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	92 92 92 92 84 76 84 76 93 116 125 100 127 116 116 110 100 127 100 91 116 117 100 127 100 91 100 91 100 91 100 91 91 100 91 91 91 91 91 91 91 91 91 91 91 91 91	eight gai hair 0 0 0 0 0 1 1 0 0 0 1 0 0 0 0 1 0	0 growt Skin 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	2.8  2.8  0  0  1  1  0  0  0  1  1  0  0  0  0	0.42  mples(Y/Fas 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	39  tt food (Re food) (Re	32  0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	1.88 Gev   1.88 Gev   1.88 Gev   1.88 Gev   1.80 Gev	BP_Diasts 880 880 880 880 880 880 880 880 880 88	G 523.74bw	D Follicle N	No Avg. F 3 3 5 5 5 2 4 4 6 6 6 6 6 7 7 1 1 5 5 2 2 8 8 3 3 1 1 3 3 5 5 5 2 2 2 7 7 8 8 6 6 6 6 6 6 6 6 7 7 1 1 5 5 5 2 2 8 8 7 7 7 8 8 8 7 7 7 8 8 8 8 7 7 8 8 8 8 7 7 8 8 8 8 7 8 8 8 8 7 8 8 8 8 9 7 8 8 8 8	18 15 16 16 16 17 17 14 17 18 20 18 18 17 16 18 17 16 18 17 18 18 17 16 18 18 17 16 11 10 10	1: 2: 1: 1: 2: 1: 1: 1: 1: 2: 2: 2: 2: 2: 2: 2: 2: 2: 2


### 3.2 System Feature

#### **PCOS Detect:**

(PCOS), also known as polycystic ovarian syndrome, is hormonal endocrine disorder among women of reproductive age. Over five million women worldwide in their reproductive age are suffering from PCOS. The most common symptoms of this disorder may include missed periods, irregular periods, or very light periods, it affects in a way that ovaries become large or may contain many cysts, it can also cause excess body hair, including the chest, stomach, and hirsutism, can cause weight gain,

especially around the abdomen, Acne or oily skin. The exact pathophysiology of PCOS is not yet known. This heterogenous disorder is characterized by the ovaries mainly. PCOS is a multifactorial and polygenic condition. Machine Learning is capable of "learning" features from very large amount through clinical practice to diagnose this disorder. This paper put forwards a solution to this problem which helps in early detection and prediction of PCOS treatment from an optimal and minimal set of parameters

Technology is changing every outlook of our lives making remarkable transformations in the healthcare industry, nowadays technology and humans are working hand in hand. For example, robots performing surgeries once seemed a fiction but now they are performing critical and complex surgeries in hospitals. Machine learning is a subclass of artificial intelligence, it helps the system learn, identify patterns of datasets, make logical decisions and performing digital analysis on digital information including words, numbers, images and clicks. Machine Learning applications mainly include image recognition, data prediction, Medical Diagnosis – Health Care and Clinical Care, etc. In this world of technology many advancements are taking place for detection of PCOS and Machine Learning algorithms are one of them



<u>Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with</u> the Polycystic Ovary Syndrome:

Polycystic ovary syndrome (PCOS) is a common endocrinopathy affecting 6–10% of reproductive-aged women and manifested by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries in its complete phenotype. Although evidence for cardiovascular events in women who were affected by PCOS during fertile age is limited, available data suggest more frequent cardiovascular disease (CVD) in classic PCOS. In young women with PCOS, multiple risk factors for CVD, including metabolic syndrome (MBS), type 2 diabetes mellitus (T2DM), dyslipidemia, abdominal obesity, and hypertension may be found, and prevention of future cardiovascular adverse effects is needed. With increased adiposity in two thirds of American PCOS women, the degree to which obesity and PCOS interact to promote premature atherosclerosis and increase cardiovascular mortality is a worldwide concern.

Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society appointed a panel to review all published evidence assessing CVD risk in PCOS vs. non-PCOS women and to recommend PCOS-related guidelines for CVD prevention. An important consideration was the broader definition of PCOS [i.e. Rotterdam 2003 or AE-PCOS 2006 vs. the more restrictive NIH 1990 criteria.

#### The Androgen Excess and PCOS Society criteria for the polycyctic ovary syndrome:

The disorder that eventually would be known as the polycystic ovary (or ovarian) syndrome (PCOS) was initially described by Stein and Leventhal in 1935 (2). However, the findings of polycystic (or cystic oophoritis or sclerocystic) ovaries dates back at least a century before that (3-5). Despite the difficulty in ascertaining the prevalence of this disorder among women there are convincing data today to suggest that it affects between 6% and 8% of women worldwide, using the National Institutes of Health (NIH) 1990 criteria (6–10), such that it can be considered one of the most common disorders of humans, and the single most common endocrine abnormality of women of reproductive age. There is little disagreement that PCOS should be considered a syndrome, that is, a collection of signs and features, where no single test is diagnostic. In essence, the whole (or global assessment) is greater than the sum of the individual parts (or features). However, establishing a clear and contemporaneous definition for what this syndrome is has important clinical and investigational implications. Clinically, diagnosing a woman as having PCOS implies an increased risk for infertility, dysfunctional bleeding, endometrial carcinoma, obesity, type 2 diabetes mellitus (DM), dyslipidemia, hypertension, and possibly cardiovascular disease (CVD). Furthermore, it has important familial implications, principally, but not exclusively, for her sisters and daughters. Finally, a diagnosis of PCOS may mandate life-long treatments (e.g., the use of insulin sensitizers), and may negatively affect her ability to access healthcare coverage, principally in capitalistic markets.

Consequently, the diagnosis of PCOS should not be assigned lightly, and diagnostic criteria should be based on robust data.

Historic usage in medical practice and/or literature: historic usage may be best reflected in the definitions presented in contemporaneous texts. However, it can be effectively argued that historic usage has limited value in yielding a contemporaneous definition of a disorder or syndrome, except to provide a reference point for the development of an updated definition.

#### The Pathogenesis of Polycystic Ovary Syndrome (PCOS): The Hypothesis of PCOS

Polycystic ovary syndrome (PCOS) is the most common endocrine disorder in reproductive aged women, with a prevalence between 5% and 15%, depending on the diagnostic criteria applied. PCOS was first described by Stein and Leventhal as a syndrome of oligo-amenorrhea and polycystic ovaries that was variably accompanied by hirsutism, acne, and obesity. Demonstration of polycystic ovaries became required for PCOS diagnosis, which required gynecologic expertise, yet polycystic ovaries were found to be variably associated with the signs and symptoms that characterize the disorder.

We then found that most hyperandrogenic women (two-thirds of those with oligo-amenorrhea, 30% of eumenorrheic ones) had this type of androgenic ovarian dysfunction and that this was independent of serum LH elevation or PCOM in about half of cases. This abnormality was termed functional ovarian hyperandrogenism (FOH), because the steroidogenic disorder is gonadotropin dependent (ie, any treatment that suppresses gonadotropin production suppresses androgen production), and there is not a requisite anatomic basis for the disorder.

Finally, the hyperandrogenism of PCOS improves during middle age, which is sometimes accompanied by normalization of menstrual regularity. These changes seem related to the fall in follicle number during the premenopausal transition, which is accompanied by falling serum inhibin-B and rising FSH levels that maintain estradiol secretion. Although hyperandrogenism may remit during menopause, lifelong metabolic dysfunction persists and may increase postmenopausal cardiovascular disease risk. Criteria for the diagnosis of postmenopausal PCOS remain to be defined.

<u>Polycystic Ovary Syndrome (PCOS): Arguably the Most Common Endocrinopathy Is</u> Associated with Significant Morbidity in Women: Women's health is about the prevention, screening, diagnosis, and treatment of disorders that are unique to women. Polycystic ovary syndrome (PCOS) is extremely prevalent and probably constitutes the most frequently encountered endocrinopathy in women of reproductive age. Primary care providers do not commonly appreciate that the syndrome is associated with significant morbidity in terms of both reproductive and nonreproductive events. Having the disorder may significantly impact the quality of life of women during the reproductive years, and it contributes to morbidity and mortality by the time of menopause. A cohort of women with PCOS who were followed for many years after wedge resection revealed several important findings by the time they reached the age of menopause. Their symptoms of PCOS had persisted over this time, they had a later menopause, and they had experienced a higher hysterectomy rate. Most importantly, there was a high prevalence of diabetes (16%) and hypertension (40%).

A uniform definition of PCOS does not exist, in large part because of its diverse and heterogeneous nature. It is clear to us, however, that the disorder is an endocrinopathy, and that it should be referred to as PCOS, a syndrome, rather than a disease. At a meeting held at the National Institutes of Health 10 years ago, there was no consensus but a general agreement that hyperandrogenism and chronic anovulation are the principal facets of the syndrome and that once other disorders (CAH, tumors) were ruled out, the diagnosis of PCOS may be presumed. In the literature, this general definition is quoted as the "NIH Consensus Statement." Indeed, this was not a consensus conference, and there was no consensus.

#### **Endocrine Disruptors and Polycystic Ovary Syndrome (PCOS):**

The female gonad appears to be a particularly sensitive target of BPA disruption, this indicated by evidence of interference with ovarian steroidogenesis, folliculogenesis, and ovarian morphology. The underlying mechanisms of BPA that impact upon ovarian function appear to be bidirectional. Specifically, *in vitro* studies have provided evidence that exposure of rat ovarian theca-interstitial cells to BPA results in elevated testosterone synthesis. Androgens interfere with BPA clearance in the liver leading to increased serum levels of BPA. Moreover, BPA alters androgen metabolism in the liver and, acting as a potent sex hormone-binding globulin (SHBG) binder, displaces androgens resulting in increased levels of serum free androgens.

Hyperandrogenaemia, insulin resistance, and chronic anovulation are the cardinal features of polycystic ovary syndrome (PCOS), the most common endocrinopathy of women of reproductive age. Insulin resistance is found in the majority of obese women with PCOS and in a significant proportion (30%) of lean women with the syndrome. Moreover, the prevalence of carbohydrate metabolism disorders, such as impaired glucose tolerance or frank diabetes mellitus, is significantly increased in women with PCOS compared with body mass index (BMI)-matched peers. Although the etiology of the syndrome remains enigmatic, the potential influence of environmental factors on PCOS development has recently been explored. BPA may contribute to the pathogenesis of the syndrome, because elevated BPA levels have been reported in women with ovulatory dysfunction compared with regularly ovulating women. Furthermore, sex is significantly associated with BPA levels given that serum BPA concentrations are significantly higher in men than in women. Recently, it was shown that exposure of neonatal rats to BPA is linked with PCOS-like syndrome and dysregulation of insulin secretion/glucose metabolism.

# Early Endocrine, Metabolic, and Sonographic Characteristics of Polycystic Ovary Syndrome (PCOS): Comparison between Nonobese and Obese Adolescents.

POLYCYSTIC OVARY SYNDROME (PCOS) is the most common endocrinopathy in women, present in 5–7% of women of reproductive age. PCOS is characterized by hyperandrogenism and chronic anovulation, and its morbidity may include hyperinsulinemia, insulin resistance, early onset of type 2 diabetes mellitus (DM), dyslipidemia, cardiovascular disease, and infertility Women with PCOS demonstrate marked clinical heterogeneity; the commonly associated features of hirsutism, acne, polycystic-appearing ovaries, obesity, and acanthosis nigricans are neither uniform nor universal.

The etiology of PCOS remains unclear. The syndrome is often perimenarcheal in onset, and similarities between the physiological changes of puberty and the pathological features of PCOS have been noted, such as the hyperpulsatile gonadotropin secretion, increased ovarian and adrenal steroidogenesis, menstrual irregularity, reduced levels of SHBG and IGFBP-1, hyperinsulinemia, and insulin resistance that develop in both conditions. Decreased levels of SHBG, hyperinsulinemia, insulin resistance, and unfavorable lipid profiles have also been demonstrated in prepubertal girls with premature adrenarche (PA) and pubertal girls with a history of PA, a condition that may herald the later development of anovulation and functional ovarian hyperandrogenism, including PCOS. Nonetheless, PCOS has not been as extensively investigated in the adolescent population. Studies have demonstrated disturbances in insulin sensitivity and insulin secretion early in the course of PCOS and indicate that similar to their adult counterparts, both lean and obese adolescent girls with PCOS are at increased risk for impaired glucose tolerance and DM.

# <u>Development of a Health-Related Quality-of-Life Questionnaire (PCOSQ) for Women with Polycystic Ovary Syndrome (PCOS).</u>

POLYCYSTIC ovary syndrome (PCOS) is the most common endocrine disorder among women of reproductive age in the developed world, affecting 5–10% of this population. The disorder exhibits a variety of symptoms including oligomenorrhea, hirsutism, and obesity, not all of which are necessarily present in any one woman. Women with PCOS may complain about irregular menstrual periods and/or heavy menstrual bleeding, infertility, excessive growth of coarse facial and body hair, obesity, oiliness of the skin, seborrhoea, and cystic acne. The impact of these symptoms on a woman's quality of life may be profound and can result in psychological distress that threatens her feminine identity. The condition may therefore result in altered self-perception, a dysfunctional family dynamic, and problems at work.

The therapy of PCOS is usually focused on ameliorating its symptoms. Effective treatment can reduce the burden of these symptoms as well as the associated psychological distress and thus improve health-related quality of life (HRQL). Although generic instruments for measuring quality of life are available, they are not designed to measure the range of health-related problems experienced by women with PCOS or to detect the changes in these problems induced by effective interventions. Accordingly, we developed the first health status measure that examines disease-related dysfunction in PCOS women for use in clinical trials and natural history studies.

# <u>Diagnosis of polycystic ovary syndrome (PCOS): revisiting the threshold values of follicle count on level for the definition of polycystic ovaries.</u>

Polycystic ovary syndrome (PCOS) is a common endocrine disorder, affecting up to 10% of women of reproductive age. Its prevalence varies according to the definition used and to the reference population.

The cardinal features of PCOS are hyperandrogenism (HA) and oligo-anovulation. The metabolic abnormalities often associated with this syndrome (obesity, insulin resistance, hyperinsulinemia and dyslipidemia) are not included in the definition of the syndrome because it is still unclear whether they are intrinsic to the disease or not. The current diagnostic classifications use HA, oligo-anovulation and polycystic ovarian morphology (PCOM) at ultrasound. Whether HA is a necessary criterion remains controversial. By allowing the diagnosis of PCOS with only two items out of the three (HA, oligo-anovulation and PCOM), the so-called Rotterdam classification includes patients without overt HA.

There is indeed an urgent need to revisit these markers, but setting thresholds to define PCOM is particular. According to their symptoms, the 240 patients included in this study were divided into three groups: group 1 (n = 105) including women without HA (clinical or biological) and with regular menses (non-PCOS group), group 2 (n = 73) including women with only HA or only oligoanovulation (presumption of PCOS) and group 3 (n = 62) including women with HA and oligoanovulation, i.e. patients with genuine PCOS.

# 4. NONFUNCTIONAL REQUIREMENTS

#### 4.1 PERFORMANCE REQUIREMENTS

The steps involved to perform the implementation of airline database are as listed below.

**A) E-R DIAGRAM**The E-R Diagram constitutes a technique for representing the logical structure of a database in a pictorial manner. This analysis is then used to organize data as a relation, normalizing relation and finally obtaining a relation database.

- **ENTITIES:** Which specify distinct real-world items in an application.
- **PROPERTIES/ATTRIBUTES:** Which specify properties of an entity and relationships.
- **RELATIONSHIPS:** Which connect entities and represent meaningful dependencies.

#### **B) NORMALIZATION:**

The basic objective of normalization is to reduce redundancy which means that information is to be stored only once. Storing information several times leads to wastage of storage space and increase in the total size of the data stored.

If a database is not properly designed it can give rise to modification anomalies. Modification anomalies arise when data is added to, changed or deleted from a database table. Similarly, in traditional databases as well as improperly designed relational databases, data redundancy can be a problem. These can be eliminated by normalizing a database.

Normalization is the process of breaking down a table into smaller tables. So that each table deals with a single theme. There are three different kinds of modifications of anomalies and formulated the first, second and third normal forms (3NF) is considered sufficient for most practical purposes. It should be considered only after a thorough analysis and complete understanding of its implications.

#### **4.2 SAFETY REQUIREMENTS**

If there is extensive damage to a wide portion of the database due to catastrophic failure, such as a disk crash, the recovery method restores a past copy of the database that was backed up to archival storage (typically tape) and reconstructs a more current state by reapplying or redoing the operations of committed transactions from the backed up log, up to the time of failure.

#### **4.3 SECURITY REQUIREMENTS**

Security systems need database storage just like many other applications. However, the special requirements of the security market mean that vendors must choose their database partner carefully.

#### 4.4 SOFTWARE QUALITY ATTRIBUTES

- **AVAILABILITY:** The website should be available on the specified date and specified time as many customers are using the platform simultaneously.
- **CORRECTNESS:** The website should reach the target audience and produce the most effective outcome of the specified problems.
- **MAINTAINABILITY:** Maintenance of the website is one of the most important aspect of the development process bonce the project is deployed.

• **USABILITY:** The outcome must reach the needs ofpeiple and people must be satisfied with the presented resaut.

Models	Accuracy				
Decision Tree	82.79				
SVC	69.05				
Random Forest	89.42				
Logistic Regression	83.32				
K Nearest Neighbors	74.34				
XGBRF	85.89				
CatBoost Classifier	92.64				




Table 2. Chi-Square Score for Top 30 Features (Generated in Jupyter Notebook)

Rank	Feature	Score Rank		Feature	Score
1	PRL(ng/mL)	9600.594	16	Vit D3 (ng/mL)	25.00828
2	No. of abortions	6899.359	17	Hair loss(Y/N)	23.56211
3	FSH(mIU/mL)	2572.754	18	Cycle length(days)	19.71094
4	II beta-HCG(mIU/mL)	1592.273	19	Height(Cm)	15.10558
5	I beta-HCG(mIU/mL)	1012.629	20	Skin darkening (Y/N)	8.910647
6	Follicle No. (L)	673.1438	21	Cycle(R/I)	8.230296
7	BP _Diastolic (mmHg)	564.5952	22	Follicle No. (R)	7.460844
8	TSH (mIU/L)	221.8157	23	FSH/LH	5.426396
9	LH(mIU/mL)	96.23587	24	Hip(inch)	5.219221
10	hair growth(Y/N)	85.66499	25	PRG(ng/mL)	4.779813
11	Weight gain(Y/N)	84.0381	26	Avg. F size (L) (mm)	3.352904
12	RBS(mg/dl)	65.01353	27	Avg. F size (R) (mm)	3.144839
13	Age (yrs)	50.85829	28	Pregnant(Y/N)	2.824165
14	Pimples(Y/N)	37.43732	29	Fast food (Y/N)	1.856357
15	Hb(g/dl)	27.7938	30	Blood Group	1.235629

Table 3. K Fold Cross Validation Scores								
	Fold 1	Fold 2	Fold 3	Fold 4	Fold 5	Mean Accuracy		
Random Forest Classifier	0.895349	0.930233	0.872093	0.918605	0.929412	0.909138		
Logistic Regression	0.918605	0.918605	0.872093	0.872093	0.917647	0.899808		
Linear SVM	0.895349	0.883721	0.872093	0.848837	0.905882	0.881176		
Radial SVM	0.941860	0.883721	0.813953	0.883721	0.882353	0.881122		
KNeighbors Classifier	0.883721	0.883721	0.837209	0.883721	0.894118	0.876498		
Gaussian Naive Bayes	0.895349	0.906977	0.779070	0.848837	0.917647	0.869576		

Table 4. Classification Report								
	Precision (Class 1, Class 2)	Recall (Class 1, Class 2)	Fscore (Class 1, Class 2)					
Linear SVM	(0.911, 0.850)	(0.911, 0.850)	(0.911, 0.850)					
Radial SVM	(0.855, 0.906)	(0.955, 0.725)	(0.902, 0.805)					
Logistic Regression	(0.888, 0.888)	(0.941, 0.800)	(0.914, 0.842)					
Random Forest Classifier	(0.891, 0.941)	(0.970, 0.800)	(0.929, 0.864)					
KNeighbors Classifier	(0.820, 0.866)	(0.941, 0.650)	(0.876, 0.742)					
Gaussian Naive Bayes	(0.923, 0.813)	(0.882, 0.875)	(0.902, 0.843)					